

World's first intranasal delivery of a proven PDE5 inhibitor for erectile dysfunction

ROXUS, ready when they are.™



Intranasal drug delivery vs. oral¹

Absorption

Drug delivery

Clinical effect



Intranasal



Direct absorption through nasal membrane

Bypasses hepatic first-pass metabolism

Leads to rapid clinical effect with much lower doses



Oral



Absorbed through the gut mucosa and enters the portal venous circulation

Undergoes hepatic first-pass metabolism in the liver, removing 90-95% of the drug

Results in delayed clinical effect (30-60 minutes)

ROXUS key clinical benefits

— Personalized medication

Designed to address patient needs related to onset, reliability, and tolerability.

— Consistent therapeutic effects²

Less variability in pharmacokinetic parameters provides more predictable patient responses.

— Lower dose required^{2,4}

Comparable plasma concentrations with 5mg intranasal versus 10mg oral, reducing overall drug exposure.

— Proven & well-tolerated²⁻⁴

Comparable efficacy to oral PDE5 inhibitors with a similar systemic adverse event profile.

— Rapid onset of action²

Under 10 minutes onset enables greater spontaneity in intimate situations.

— Alternative delivery route

Suitable for patients with dysphagia or difficulty swallowing.



The ROXUS difference



Features

Onset time

Under 10 minutes

30-120 minutes

Route of administration

Intranasal

Oral

Delivery route

Efficient absorption through nasal tissue

Digestive system and liver metabolism

Dosage

Lower systemic dose required

Other PDE5 inhibitors

Patient eligibility

Patients may be eligible for intranasal treatment with ROXUS when:

- ✓ Insufficient response to existing therapies, including delayed onset or inconsistent effectiveness.
- ✓ Clinical need for an alternative formulation or delivery route not available with approved products.
- ✓ Intolerable adverse effects experienced with oral PDE5 inhibitors.


Dosing

- 5mg prn (2 applications with one in each nostril)
- 2.5mg delivered per 130µL spray



From desire to action in minutes⁴

Three simple steps from spray to confidence.



How it works

- 1 Spray**
Use once per nostril as directed.
- 2 Absorb**
Rapid uptake via nasal membranes.
- 3 Perform**
Noticeable results within 10 minutes.

Contains a clinically proven PDE5 inhibitor via nasal delivery.

Prescribing ROXUS

ROXUS is now available direct to patients. Patients are evaluated through telehealth, and prescriptions are filled through a licensed 503A compounding pharmacy. For full prescribing information, clinical data, and downloadable patient resources, visit the [ROXUS HCP Portal at roxus.com/prescriber](https://roxus.com/prescriber) (NPI verification required).

REFERENCES: 1. Wolfe, T.R. (2022). Not Just a Single Squirt: Understanding Nasal Drug Delivery. EMS Airway. Available at: <https://emsairway.com/2022/04/01/understanding-nasal-drug-delivery/>. 2. Wang, J. et al. "Pharmacokinetics Comparison of Vardenafil as Administered by an Intranasal Spray Formulation vs a 10-mg Oral Tablet." *The Journal of Sexual Medicine* 00, no. 00 (2023) 1–6. <https://doi.org/10.1093/jsxmed/qdad056>. 3. E. Chung et al. 2025. Pharmacokinetics of an oral versus intranasal delivered formulation of the phosphodiesterase type 5 inhibitor vardenafil in healthy men – a phase 1, randomized open label, single dose, two period, two treatment, cross-over study. *European Journal of Pharmaceutical Sciences* 213 (2025) 107226. 4. Data on file.

ROXUS is a compounded medication. Compounded drugs are not FDA-approved and are not reviewed for safety, effectiveness, or quality. They are prepared for a specific patient based on a valid prescription. Do not use ROXUS with nitrates or guanylate cyclase stimulators. Seek immediate help for erections lasting over four hours. Stop use and contact your doctor for sudden vision or hearing loss. Always follow medical guidance.

ROXUS and ROXUS, READY WHEN THEY ARE are trademarks of LTR Pharma Ltd.
For more information, visit www.roxus.com.
LTR-US-005-V1.